Biomea Fusion, Inc. BMEA
Institutional shares held
19 Million
289K
calls
336K
puts
Total value of holdings
$24.3M
$369K
calls
$429K
puts
Market Cap
$37.5M
29,290,600
Shares Out.
Institutional ownership
64.79%
# of Institutions
86
We take great care to ensure that the data presented and summarized in this overview for Biomea Fusion, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BMEA
View all-
Cormorant Asset Management, LP Boston, MA3.57MShares$4.57 Million1.15% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$2.78 Million0.0% of portfolio
-
Aisling Capital Management LP New York, NY2.05MShares$2.62 Million0.94% of portfolio
-
Heights Capital Management, Inc San Francisco, CA1.44MShares$1.84 Million0.8% of portfolio
-
Woodline Partners LP San Francisco, CA1.3MShares$1.67 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny596KShares$762,7520.0% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA572KShares$732,2150.0% of portfolio
-
Two Sigma Investments, LP New York, NY563KShares$720,5990.0% of portfolio
-
Geode Capital Management, LLC Boston, MA447KShares$571,9980.0% of portfolio
Latest Institutional Activity in BMEA
Top Purchases
Top Sells
About BMEA
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Insider Transactions at BMEA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2025
|
Michael J.M. Hitchcock Interim CEO |
BUY
Open market or private purchase
|
Direct |
100,000
+46.51%
|
$0
$0.99 P/Share
|
|
Dec 01
2025
|
Rainer M Erdtmann |
BUY
Open market or private purchase
|
Direct |
10,000
+1.42%
|
$10,000
$1.05 P/Share
|
|
Nov 28
2025
|
Rainer M Erdtmann |
BUY
Open market or private purchase
|
Direct |
40,000
+5.53%
|
$40,000
$1.1 P/Share
|
|
Jan 31
2025
|
Rainer M Erdtmann |
BUY
Bona fide gift
|
Indirect |
30,000
+33.56%
|
-
|
|
Jan 31
2025
|
Rainer M Erdtmann |
SELL
Bona fide gift
|
Direct |
30,000
-1.51%
|
-
|
|
Jan 28
2025
|
Rainer M Erdtmann |
SELL
Bona fide gift
|
Direct |
40,000
-5.61%
|
-
|
|
Nov 30
2024
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
495
+1.14%
|
$2,970
$6.15 P/Share
|
|
Sep 30
2024
|
Michael J.M. Hitchcock Interim CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+40.0%
|
$100,000
$10.06 P/Share
|
|
Jun 11
2024
|
Franco Valle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
12,509
+22.74%
|
$50,036
$4.43 P/Share
|
|
May 31
2024
|
Juan Pablo Frias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
349
+50.0%
|
$2,792
$8.94 P/Share
|
|
May 31
2024
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,448
+12.92%
|
$13,344
$3.78 P/Share
|
|
Dec 29
2023
|
Rainer M Erdtmann |
SELL
Bona fide gift
|
Direct |
21,000
-0.72%
|
-
|
|
Dec 29
2023
|
Rainer M Erdtmann |
BUY
Bona fide gift
|
Indirect |
9,000
+23.45%
|
-
|
|
Nov 30
2023
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,345
+5.0%
|
$4,035
$3.78 P/Share
|
|
Jun 01
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
50,000
-1.41%
|
$1,700,000
$34.56 P/Share
|
|
May 31
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
75,000
-2.07%
|
$2,475,000
$33.81 P/Share
|
|
May 31
2023
|
Franco Valle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,273
+15.01%
|
$12,819
$3.78 P/Share
|
|
May 12
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
25,000
-0.68%
|
$825,000
$33.84 P/Share
|
|
May 09
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
150,000
-3.95%
|
$5,100,000
$34.5 P/Share
|
|
May 08
2023
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
100,000
-2.56%
|
$3,300,000
$33.99 P/Share
|
Last 12 Months Summary
Buy / Acquisition
180K
Shares
From
3
Insiders
| Bona fide gift | 30K shares |
|---|---|
| Open market or private purchase | 150K shares |
Sell / Disposition
70K
Shares
From
1
Insiders
| Bona fide gift | 70K shares |
|---|